231. α1−アンチトリプシン欠乏症 Alpha-1-antitrypsin deficiency Clinical trials / Disease details


臨床試験数 : 93 薬物数 : 77 - (DrugBank : 8) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 36

  
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003650-92-SE
(EUCTR)
08/05/202009/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
2EUCTR2019-003650-92-IE
(EUCTR)
09/04/202010/03/2020Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
3EUCTR2019-003650-92-GB
(EUCTR)
28/02/202009/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
4EUCTR2019-003650-92-DE
(EUCTR)
11/02/202004/12/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZGenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ Subjects Alpha-1 Antitrypsin Deficiency;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]Product Code: VX-814
INN or Proposed INN: VX-814
Vertex Pharmaceuticals IncorporatedNULLNot RecruitingFemale: yes
Male: yes
43Phase 2United States;Ireland;Netherlands;Germany;United Kingdom;Sweden
5NCT04167345
(ClinicalTrials.gov)
January 13, 202015/11/2019Evaluation of the Efficacy and Safety of VX-814 in Subjects With the PiZZ GenotypeA Phase 2, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of VX-814 in PiZZ SubjectsAlpha 1-Antitrypsin DeficiencyDrug: VX-814;Drug: PlaceboVertex Pharmaceuticals IncorporatedNULLTerminated18 Years80 YearsAll48Phase 2United States;Canada;Germany;Ireland